You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • FRI0161 A Phase 1B/2A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XMAB®5871 in Patients with Rheumatoid Arthritis

Article metrics

Article menu
Download PDFPDF
Poster Presentations
Rheumatoid arthritis - other biologic treatment
FRI0161 A Phase 1B/2A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XMAB®5871 in Patients with Rheumatoid Arthritis

 

Online download statistics by month:

Online download statistics by month: June 2015 to March 2024

AbstractFullPdf
Jun 20151301
Aug 2015401
Sep 20151002
Nov 2015300
Dec 2015902
Jan 2016701
Feb 2016800
Mar 20161201
Apr 20161300
May 2016700
Jun 20161200
Jul 20161500
Aug 2016100
Sep 2016300
Oct 2016700
Nov 2016901
Dec 2016300
Jan 20171200
Feb 2017800
Mar 20171202
Apr 20171902
May 2017300
Jun 2017400
Jul 2017202
Aug 20171201
Sep 20171400
Oct 2017400
Nov 20172801
Dec 2017400
Jan 20181000
Feb 2018200
Mar 20181602
Apr 20181000
May 2018600
Jun 2018200
Jul 2018400
Aug 20181200
Sep 2018200
Oct 20181001
Nov 20182400
Dec 20181000
Jan 2019800
Feb 2019600
Mar 2019400
Apr 20191200
May 2019200
Jul 2019400
Aug 20192400
Sep 2019500
Oct 2019600
Nov 2019300
Dec 2019600
Jan 20202400
Feb 2020200
Mar 2020700
Apr 20201201
May 2020400
Jun 20201600
Jul 2020600
Aug 2020200
Sep 20202800
Oct 2020600
Nov 20202400
Dec 2020301
Jan 2021600
Feb 2021601
Apr 20211001
May 20211701
Jun 2021500
Sep 2021100
Oct 20211200
Nov 20214000
Dec 2021800
Jan 2022500
Feb 2022600
Mar 20221501
Apr 2022900
May 20221200
Jun 2022500
Jul 20221300
Aug 20221200
Sep 20221000
Oct 20222102
Nov 20222800
Dec 20222300
Jan 20233702
Feb 2023800
Mar 20231100
Apr 20231401
May 20232600
Jun 20232500
Jul 20232500
Aug 20231600
Sep 20232800
Oct 20231500
Nov 20231800
Dec 20232502
Jan 20241800
Feb 20243402
Mar 20241600
Total1160035